Erratum
10 October 2022
Diversity, equity, and inclusion in gastroenterology and hepatology: A survey of where we stand
Harman K. Rahal, James H. Tabibian, Rachel B. Issaka, Sandra Quezada, Darrell M. Gray, Sophie Balzora, Liu Yang, Jayraan Badiee, Folasade P. May – 10 October 2022
HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB‐4 scores
Tung Huynh, Stephanie Ma, Ke‐Qin Hu – 10 October 2022 – Direct acting antiviral treatment (DAA) has been the standard of care for hepatitis C virus (HCV) infection, but its long‐term benefits in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) improvement and hepatic fibrosis assessed by aspartate aminotransferase–to–platelet ratio index (APRI) and Fibrosis‐4 index (FIB‐4) scores remain unknown.
Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascites
Cristina Ripoll, Luis Ibáñez‐Samaniego, Beatrix Neumann, Javier Vaquero, Robin Greinert, Rafael Bañares, Alexander Zipprich – 10 October 2022 – The aim of this study was to evaluate potential criteria for defining hyperdynamic circulation in patients with cirrhosis according to the severity of ascites and its association with the activation of vasoactive systems and markers of systemic inflammation. Cross‐sectional study of patients with cirrhosis and right heart catheter measurement from two different academic centers.
Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers
Scott McHenry, Xiaoyu Zong, Mengyao Shi, Cassandra D.L Fritz, Katrina S. Pedersen, Linda R. Peterson, Jeffrey K. Lee, Ryan C. Fields, Nicholas O. Davidson, Yin Cao – 10 October 2022 – Metabolic syndrome may contribute to the rising incidence of multiple gastrointestinal (GI) cancers in recent birth cohorts. However, other than hepatocellular carcinoma, the association between nonalcoholic fatty liver disease (NAFLD) and risk of non‐liver GI cancers is unexplored.
Psychosocial considerations in pediatric autoimmune liver disease
Brianna C. M. Wellen, Henry C. Lin, Jacklyn E. Stellway – 9 October 2022
Validation of novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study
Jessica Howell, Huy Van, Minh Pham, Rohit Sawhney, Fan Li, Purnima Bhat, John Lubel, William Kemp, Stephen Bloom, Avik Majumdar, Geoff McCaughan, Samuel Hall, Timothy Spelman, Joseph S. Doyle, Margaret Hellard, Kumar Visvanathan, Alexander J. Thompson, Heidi E. Drummer, David Anderson – 9 October 2022
Posttransplant considerations in autoimmune liver disease: Recurrence of disease and de novo
Alexis Gumm, Antonio Perez‐Atayde, Andrew Wehrman – 9 October 2022
Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model
Anahita Rabiee, Yanhong Deng, Maria Ciarleglio, Jean L. Chan, Monica Pons, Joan Genesca, Guadalupe Garcia‐Tsao – 9 October 2022 – Clinically significant portal hypertension (CSPH), defined as hepatic venous pressure gradient (HVPG) ≥ 10 mm Hg, identifies patients with compensated cirrhosis at a high risk of decompensation. However, HVPG is an invasive and nuanced method.
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
Dawei Ding, Guanya Guo, Yansheng Liu, Linhua Zheng, Gui Jia, Juan Deng, Ruiqing Sun, Xiufang Wang, Changcun Guo, Yulong Shang, Ying Han – 9 October 2022 – Fenofibrate (FF) has shown potential benefits in patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid (UDCA). However, the efficacy and safety of FF in patients with cirrhosis remain unclear.